Luteinizing hormone releasing hormone antagonist peptides
CA 2108977 C · Owner: Zentaris Gmbh · Inventors: Deghenghi, Romano
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A luteinizing hormone releasing hormone antagonist peptide is provided which effectively decreases plasma levels of estrogens and androgens. The peptide exhibits increased levels of potency while at the same time minimizing histamine releasing properties, vascular permeability (or edematogenic effects) hypotension, poor , water solubility an inadequate duration of action associated with luteinizing hormone releasing hormone antagonist peptides of the past.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 1992 and granted December 17, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 17, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.